Myeloid Therapeutics to Participate at Jefferies London Healthcare Conference
CAMBRIDGE, Mass, Nov. 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that the Company will participate at the Jefferies London Healthcare Conference taking place from November 15-17, 2022 in London. Company management will meet one-on-one with investors during the conference.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases. Integrating the fields of RNA, immunology and medicine, the Company’s proprietary platform provides clinical solutions by matching therapeutic modalities to disease conditions, including use of autologous cell therapies, in vivo cell programming using mRNA, RNA-based gene-editing using RetroT™ and multi-targeted biologics.
Investor and Media Contact